GSK expands RSV vaccine to younger adults in US, targeting high-risk 18–49 age group
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
Previously, Arexvy was authorized for adults 60 and older, and for those 50–59 with heightened risk
The decision marks a pivotal moment for the Massachusetts-based biotech giant
The recommendation covers FYLREVY 14.2 mg and 18.9 mg for non-hysterectomised postmenopausal women experiencing oestrogen deficiency symptoms at least 12 months after their last menses
The newly certified kits are designed for early detection and large-scale screening programs
WCK 5222 is the first New Chemical Entity (NCE) discovered and developed in India to be submitted for pan-European marketing authorisation
Under the agreement, AVT06 is licensed to enter the US market in the fourth quarter of 2026
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Subscribe To Our Newsletter & Stay Updated